The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2021 | Treatments for patients with NSCLC carrying EGFR exon 20 insertions
Robin Cornelissen, MD, PhD, Erasmus University Rotterdam, Rotterdam, Netherlands, discusses the efficacy of treatments for patients with non-small cell lung cancer (NSCLC) carrying exon 20 insertions in the EGFR gene. Although they are not as efficacious as other targeted therapies, drugs targeting exon 20 insertions reduce disease burden and have increased progression-free survival (PFS) for this patient population. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.
